Results 51 to 60 of about 2,206,632 (403)

Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center

npj Vaccines, 2021
The RV144 HIV-1 vaccine trial has been the only clinical trial to date that has shown any degree of efficacy and associated with the presence of vaccine-elicited HIV-1 envelope-specific binding antibody and CD4+ T-cell responses.
Leila Eslamizar, Constantinos Petrovas, David J. Leggat, Kathryn Furr, Michelle L. Lifton, Gail Levine, Steven Ma, Christopher Fletez-Brant, Wesley Hoyland, Madhu Prabhakaran, Sandeep Narpala, Kristin Boswell, Takuya Yamamoto, Hua-Xin Liao, David Pickup, Elizabeth Ramsburg, Laura Sutherland, Adrian McDermott, Mario Roederer, David Montefiori, Richard A. Koup, Barton F. Haynes, Norman L. Letvin, Sampa Santra   +23 more
doaj   +1 more source

Community perceptions of a malaria vaccine in the Kintampo districts of Ghana. [PDF]

, 2013
BACKGROUND: Malaria remains the leading cause of morbidity and mortality in sub-Saharan Africa despite tools currently available for its control. Making malaria vaccine available for routine use will be a major hallmark, but its acceptance by community ...
A Bingham, A Dodoo, A Launiala, A Olotu, AK Rowe, AS Jegede, C Wongsrichanalai, CA Baume, CA de Quadros, Dan-Bright S Dzorgbo, DB Dery, DI Ojakaa, E Klinkenberg, F Nuwaha, FN Binka, G GSS, Kojo A Senah, KP Asante, Kwaku P Asante, Lawrence G Febir, PW Chung, RW Snow, S Owusu-Agyei, S Owusu-Agyei, S Owusu-Agyei, Seth Owusu-Agyei, ST Agnandji, ST Agnandji, TE Nkya, Timothy S Letsa, WHO   +30 more
core   +2 more sources

Vaccine hesitancy: Beliefs and barriers associated with COVID‐19 vaccination among Egyptian medical students

Journal of Medical Virology, 2021
Vaccine hesitancy poses serious challenges for achieving coverage for population immunity. It is necessary to achieve high COVID‐19 vaccination acceptance rates and medical students’ coverage as future health care providers.
Shimaa M. Saied, E. Saied, I. Kabbash, Sanaa A Abdo   +3 more
semanticscholar   +1 more source

Meningococcal serogroup B vaccines: Estimating breadth of coverage

Human Vaccines & Immunotherapeutics, 2017
Neisseria meningitidis serogroup B (MenB) is an important cause of invasive meningococcal disease. The development of safe and effective vaccines with activity across the diversity of MenB strains has been challenging.
Robert G. K. Donald, Julio Cesar Hawkins, Li Hao, Paul Liberator, Thomas R. Jones, Shannon L. Harris, John L. Perez, Joseph J. Eiden, Kathrin U. Jansen, Annaliesa S. Anderson   +9 more
doaj   +1 more source

Conducting a phase III clinical trial in children during the COVID- 19 pandemic: Experience and lessons learnt from a clinical research facility of Nepal

Human Vaccines & Immunotherapeutics, 2023
Clinical trials in humans are vital to test safety and efficacy of new interventions and are accompanied with the complexity of related regulatory guidelines, stringent time frame and financial burden particularly when participants are children ...
Ram Hari Chapagain, Jessica Maharjan, Santosh Adhikari, Prabhat Thapa, Kshitij Kunwar, Bishnu Rath Giri, Nisha Jyoti Shrestha, Anil Kumar Shrestha, Sanjeet Kumar Shrestha, Suresh Man Tamang, Haeun Cho, Eun Lyeong Park, Jiyoung Lee, Jinae Lee, Deok Ryun Kim, Jae Seung Yang, Tarun Saluja, Anh Wartel, Julia Lynch, Katerina Rok Song   +19 more
doaj   +1 more source

HPV vaccine [PDF]

, 2018
Human Papilloma virus has been related not only to 98% of cervical cancers but also to mouth and throat cancers. There is a vaccine that prevents contraction of this virus: HPV vaccine.
vivas, alejandra
core   +1 more source

Racing against COVID-19: a vaccines strategy for Europe. Bruegel Policy Contribution Issue n˚7 | April 2020 [PDF]

, 2020
The fast development of vaccines is an essential part of the long-term solution to COVID-19, but vaccine development has high costs and carries the risk of high failure rates.
Veugelers, Reinhilde, Zachmann, Georg.
core   +1 more source

Barriers and facilitators to HPV vaccination in primary care practices: A mixed methods study using the Consolidated Framework for Implementation Research [PDF]

, 2018
Background In the United States, the effective, safe huma papilloma virus (HPV) vaccine is underused and opportunities to prevent cancer continue to be missed.
Dodd, Sherry, Garbutt, Jane M, Kulka, Katharine, Lee, Amanda A, Lobb, Rebecca, Walling, Emily   +5 more
core   +2 more sources

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Science, 2021
Description Antibody levels predict vaccine efficacy Symptomatic COVID-19 infection can be prevented by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.
P. Gilbert, D. Montefiori, A. McDermott, Y. Fong, D. Benkeser, Wei-zhi Deng, Honghong Zhou, Christopher R. Houchens, Karen Martins, L. Jayashankar, F. Castellino, B. Flach, Bob C. Lin, S. O'connell, C. McDanal, Amanda Eaton, M. Sarzotti-Kelsoe, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars van der Laan, N. Hejazi, C. Huynh, Jacqueline Miller, Hana M. El Sahly, L. Baden, Mira Baron, Luis I. De La Cruz, C. Gay, Spyros A. Kalams, Colleen F. Kelley, M. Andrasik, J. Kublin, L. Corey, K. Neuzil, Lindsay N. Carpp, R. Pajon, D. Follmann, R. Donis, R. Koup   +39 more
semanticscholar   +1 more source

By dawn or dusk—how circadian timing rewrites bacterial infection outcomes

FEBS Letters, EarlyView.
The circadian clock shapes immune function, yet its influence on infection outcomes is only beginning to be understood. This review highlights how circadian timing alters host responses to the bacterial pathogens Salmonella enterica, Listeria monocytogenes, and Streptococcus pneumoniae revealing that the effectiveness of immune defense depends not only
Devons Mo, Catherine S. Palmer, Jacqueline M. Kimmey   +2 more
wiley   +1 more source